Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates
Intellia Therapeutics (NASDAQ:NTLA) will present its Q3 2020 financial results and operational highlights on November 5, 2020, at 8 a.m. ET. Interested participants can join the call by dialing 1-877-317-6789 in the U.S. or 1-412-317-6789 internationally. A replay will be available post-call on the company's website from 12 p.m. ET the same day. Intellia is focused on developing curative therapeutics using CRISPR/Cas9 technology, aiming to revolutionize medicine by permanently editing disease-related genes with a single treatment.
- None.
- None.
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its third quarter 2020 financial results and operational highlights in a conference call on November 5, 2020 at 8 a.m. ET.
To join the call:
- U.S. callers should dial 1-877-317-6789 and international callers should dial 1-412-317-6789, approximately five minutes before the call.
- All participants should ask to be connected to the Intellia Therapeutics conference call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com, beginning on November 5, 2020 at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.
Intellia Contacts:
Investor Contact:
Lina Li
Associate Director, Investor Relations
+1 857-706-1612
lina.li@intelliatx.com
Media Contact:
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com
FAQ
When will Intellia Therapeutics announce its Q3 2020 financial results?
How can I join the Intellia Therapeutics conference call?
Where can I find the replay of the Intellia call after it concludes?
What technology does Intellia Therapeutics focus on?
